Trans [epsilon] viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model

As Alzheimer's disease (AD) induces several cellular and molecular damages, it could be interesting to use multi-target molecules for therapeutics. We previously published that trans [epsilon]-viniferin induced the disaggregation of A[beta].sub.42 peptide and inhibited the inflammatory response...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2019-02, Vol.14 (2), p.e0212663
Main Authors: Caillaud, Martial, Guillard, Jérôme, Richard, Damien, Milin, Serge, Chassaing, Damien, Paccalin, Marc, Page, Guylène, Rioux Bilan, Agnès
Format: Article
Language:English
Subjects:
Advertising executives
Alzheimer's disease
Animal genetic engineering
Astrocytes
Beverages
EDTA
Genetic aspects
Genetic engineering
Genetic research
Inflammation
Laboratory rats
Peptides
Phenols (Class of compounds)
Polyphenols
Resveratrol
Therapeutics
Vegetables
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As Alzheimer's disease (AD) induces several cellular and molecular damages, it could be interesting to use multi-target molecules for therapeutics. We previously published that trans [epsilon]-viniferin induced the disaggregation of A[beta].sub.42 peptide and inhibited the inflammatory response in primary cellular model of AD. Here, effects of this stilbenoid were evaluated in transgenic APPswePS1dE9 mice. We report that trans [epsilon]-viniferin could go through the blood brain barrier, reduces size and density of amyloid deposits and decreases reactivity of astrocytes and microglia, after a weekly intraperitoneal injection at 10 mg/kg from 3 to 6 months of age.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0212663